ArticleClinical parkinsonism & related disorders2022
Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients.
Article in Clinical parkinsonism & related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Cognitive Outcomes of Advanced Therapies in Parkinson's Disease: A Systematic Review of Apomorphine and Levodopa-Carbidopa Intestinal Gel Therapies.European journal of neurology · 2025Pooled it
- Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson's Disease: A Systematic Review.Brain sciences · 2026Review
- Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial.Neurology and therapy · 2026Article
- Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS-Park Cohort.Movement disorders clinical practice · 2026Observational
- Therapeutic Spectrum of Intermittent Apomorphine in Parkinson's Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses.Noro psikiyatri arsivi · 2026Article
- How to Use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson's Disease.Movement disorders clinical practice · 2024Review
- Apomorphine is a potent inhibitor of ferroptosis independent of dopaminergic receptors.Scientific reports · 2024Article
- Personality and quality-of-life improvement after apomorphine infusion in Parkinson's disease.Brain communications · 2024Article
- Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.Neurology · 2023Article
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.Journal of neural transmission (Vienna, Austria : 1996) · 2023Observational
- Night-Time Apomorphine Infusion: Who Are the Best Candidates?Movement disorders clinical practice · 2023Article
- Impaired night-time mobility in patients with Parkinson's disease: a systematic review.Frontiers in aging neuroscience · 2023Review
- Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease.Neuropsychiatric disease and treatment · 2023Review
- [Apomorphine and frontal dysfunction in Parkinson's disease].Revista de neurologia · 2022Review
- Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study.Diagnostics (Basel, Switzerland) · 2022Article
- Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.Brain sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease (PD) patients usually start treatment with apomorphine infusion (APO) in later stages of advanced PD (aPD). This timing limits the evaluation of its motor efficacy and other potential clinical benefits throughout the full course of aPD.
methodsWe prospectively analyzed the effect of APO on motor and non-motor symptoms, cognitive function and quality of life (QoL) in 22 PD patients with early stage aPD, defined as: age < 71 years and diagnosis of aPD for < 3 years.
resultsAt baseline, mean (±SD) age and disease duration were 59.4 ± 6.1 and 8.7 ± 3.5 years, respectively. After 6 months of APO treatment, daily
conclusionIn patients with early stage initial aPD, s substantial benefit of APO was observed on motor symptoms, driven by a 70% reduction in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.